Showing results (11-20 of 64) with videos related to

Sort By:
Pageof 7
Primary Care Diabetes|August 23, 2020
Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?Samuel Seidu, Linda Mellbin, Marcel Kaiser, et al.
Reviews in Endocrine & Metabolic Disorders|March 6, 2010
Overview of the importance of glycaemic control for cardiovascular events in the in-and out-patient settingMatteo Anselmino, Klas Malmberg, Linda Mellbin, et al.
Diabetes & Vascular Disease Research|September 5, 2014
The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term managementPamela Katz, Lawrence A Leiter, Linda Mellbin, et al.
International Journal of Cardiology|June 4, 2018
Percutaneous coronary intervention versus conservative treatment for non ST-segment elevation myocardial infarction in patients above 80 years of agePeter Reinius, Linda Mellbin, Martin J Holzmann, et al.
Diabetes & Vascular Disease Research|October 30, 2008
Implications of abnormal glucose metabolism in patients with coronary artery diseaseMatteo Anselmino, Märit Wallander, Anna Norhammar, et al.
Heart, Lung & Circulation|August 16, 2016
Copeptin in Heart Failure, Post-Left Ventricular Assist Device and Post-Heart TransplantationStanislava Zabarovskaja, Camilla Hage, Anders Gabrielsen, et al.
Diabetes & Vascular Disease Research|May 22, 2014
The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI studyCamilla Hage, Kerstin Brismar, Pia Lundman, et al.
Molecular and Cellular Endocrinology|August 4, 2022
Sitagliptin reduces FAP-activity and increases intact FGF21 levels in patients with newly detected glucose abnormalitiesAnne K N Pedersen, Camilla Hage, Niels Jessen, et al.
Endocrinology, Diabetes & Metabolism|July 19, 2021
A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular diseaseLyndon Marc Evans, Linda Mellbin, Pierre Johansen, et al.
European Journal of Preventive Cardiology|October 6, 2018
Effectiveness of different outreach strategies to identify individuals at high risk of diabetes in a heterogeneous population: a study in the Swedish municipality of SödertäljeBahira Shahim, Sofia Hasselberg, Oscar Boldt-Christmas, et al.
Pageof 7